Cidara Therapeutics (NYSE: QGEN) and Qiagen (NYSE: QGEN) are both medical companies, but what is the superior company? We will compare the two companies based on the strength of their profitability, institutional ownership, earnings, recommendations from analysts, risks, dividends and valuation.
This table compares Cidara Therapeutics and the net margins of Qiagen, the return on equity and the return on assets.
|Net margins||Return on equity||Return on assets|
|Cidara Therapeutics||N / A||-96.55%||-72.59%|
This is a summary of the current ratings and target prices for Cidara Therapeutics and Qiagen, as reported by MarketBeat.
|Sales reviews||Keep ratings||Buy ratings||Strong sales figures||Review score|
Cidara Therapeutics currently has a consensus target price of $ 13.25, suggesting a potential benefit of 201.14%. Qiagen has a consensus target price of $ 38.75, suggesting a potential advantage of 1.33%. Given the stronger consensus of Cidara Therapeutics and a higher possible benefit, stock analysts believe that Cidara Therapeutics is more beneficial than Qiagen.
Insider & institutional property
56.0% of the shares in Cidara Therapeutics are held by institutional investors. By comparison, 66.1% of Qiagen shares are held by institutional investors. 15.2% of Cidara Therapeutics shares are owned by insiders of companies. By comparison, 9.0% of Qiagen shares are owned by insiders of companies. Strong institutional ownership is an indication that donations, hedge funds and large money managers believe that a company is ready for long-term growth.
Volatility and risk
Cidara Therapeutics has a beta of 1.99, which means that the share price is 99% more volatile than the S & P 500. In terms of comparison Qiagen has a beta of 1.1, which means that the share price is 10% volatile than the S & P P 500.
Income and appreciation
This table compares the turnover, the profit per share and the valuation of Cidara Therapeutics and Qiagen.
|Gross income||Price / sales ratio||Net income||Profit per share||Price / profit ratio|
|Cidara Therapeutics||N / A||N / A||– $ 55.72 million||($ 3.18)||-1.38|
|Qiagen||$ 1.42 billion||6.16||$ 40.39 million||$ 1.27||30.11|
Qiagen has higher income and income than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two shares.
Qiagen defeats Cidara Therapeutics on 8 of the 13 factors that are compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of anti-infectives for the treatment of diseases. The lead product candidate is rezafungin acetate, a molecule in the class of antifungal agents of echinocandin for the treatment and prevention of severe invasive fungal infections, including candidemia and invasive candidiasis, fungal infections accompanied by high mortality rates. It also develops antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also drive a patient's immune system to attack and eliminate bacterial, fungal or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed the name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
QIAGEN N.V. provides examples for insight solutions that turn biological materials into molecular insights worldwide. The company offers exemplary technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA clearance after polymerase chain reaction (PCR) and sequencing, target enrichment and library preparation for sequencing applications; and assay technology solutions. It also offers Ingenuity Variant Analysis, a cloud-based platform that interprets data from the next-generation analysis (NGS); QIAGEN Clinical Insight, an evidence-based solution for decision making; CLC Genomics Workbench for the analysis and visualization of data from different NGS platforms; and GeneGlobe, a web-based portal that allows researchers to search and select gene- and pathway-specific solutions based on pre-designed and adapted PCR assay kits, NGS assay panels and other products. In addition, the company offers instrumentation systems for laboratories. The automation platforms include QIAsymphony, a modular system; GenReader NGS system, an example of insight NGS solution for laboratories to deliver useful results; QIAcube robotic workstations, which offer versatile solutions for automated sample processing; QIAx cell for separation of nucleic acids; QIAgility, a table model instrument for PCR setup; and ESEQuant instruments that enable optical measurements for point-of-need molecular testing in medical practices, first aid departments, remote areas and other applications. It serves molecular diagnostics, applied testing, pharma and academic clients. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncological therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Get news and ratings for Cidara Therapeutics Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Cidara Therapeutics and related companies with the FREE daily email newsletter from MarketBeat.com.